Platinum-containing regimens for metastatic breast cancer-Reference-Cited by-同舟云学术

Platinum-containing regimens for metastatic breast cancer

Published:2017-06-23 Issue:8 Volume:2017 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Egger Sam J¹,Willson Melina L²,Morgan Jenna³,Walker Harriet S³,Carrick Sue⁴⁵,Ghersi Davina⁶⁷,Wilcken Nicholas⁸⁹

Affiliation:

1. Cancer Council NSW; Cancer Research Division; 153 Dowling Street Sydney NSW Australia 2092

2. NHMRC Clinical Trials Centre, The University of Sydney; Systematic Reviews and Health Technology Assessments; Locked Bag 77 Sydney NSW Australia 1450

3. University of Sheffield; Academic Unit of Surgical Oncology, Department of Oncology; Sheffield South Yorkshire UK S10 2RX

4. The University of Melbourne; Twins Research Australia, Melbourne School of Population and Global Health; Melbourne Victoria Australia

5. The University Sydney; The Hub, Charles Perkins Centre; Sydney NSW Australia

6. National Health and Medical Research Council; Research Policy and Translation; 16 Marcus Clarke Street Canberra ACT Australia 2601

7. The University of Sydney; NHMRC Clinical Trials Centre; Sydney Australia

8. Westmead Hospital; Medical Oncology; Westmead NSW Australia 2145

9. The University of Sydney; Sydney Medical School; Sydney Australia

Publisher

Wiley

Subject

Pharmacology (medical)

Link

https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003374.pub4/epdf/full

Reference86 articles.

1. A randomized phase II non-comparative study of pemetrexed-carboplatin and gemcitabine-vinorelbine in anthracycline- and taxane-pretreated advanced breast cancer patients;Amadori;International Journal of Oncology,2013

2. A randomized phase II study of pemetrexed-carboplatin and gemcitabine-vinorelbine in patients with anthracycline- and taxane-pretreated advanced breast cancer;Amadori;Journal of Clinical Oncology,2011

3. NCT00325234 Pemetrexed-carboplatin and gemcitabine-vinorelbine in advanced breast cancer clinicaltrials.gov/ct2/show/results/NCT00325234

4. Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design;Berruti;Journal of Clinical Oncology,2002

5. Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design;Berruti;Journal of Clinical Oncology,2002

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mexican breast cancer consensus. Management of advanced breast cancer;Gaceta Mexicana de Oncolog�a;2024-06-25

2. Cisplatin Monotherapy as a Treatment Option for Patients with HER-2 Negative Breast Cancer Experiencing Hepatic Visceral Crisis or Impending Visceral Crisis;Oncology and Therapy;2024-06-04

3. Transcriptomic Changes in Cisplatin-Resistant MCF-7 Cells;International Journal of Molecular Sciences;2024-03-29

4. SEOM–GEICAM–SOLTI clinical guidelines in advanced breast cancer (2022);Clinical and Translational Oncology;2023-05-06

5. Outcomes of patients with HER2-negative metastatic breast cancer after platinum- and non-platinum-based first-line chemotherapy among patients with and without pathogenic germline BRCA1/2 mutations;British Journal of Cancer;2022-10-07